Format

Send to

Choose Destination
Blood. 2018 Dec 13;132(24):2608-2612. doi: 10.1182/blood-2018-07-863241. Epub 2018 Oct 26.

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.

Author information

1
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and.
2
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.
PMID:
30366921
PMCID:
PMC6293872
[Available on 2019-12-13]
DOI:
10.1182/blood-2018-07-863241
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center